These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11055323)

  • 21. A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency.
    Yeung TW; Li RH; Lee VC; Ho PC; Ng EH
    J Clin Endocrinol Metab; 2013 Jan; 98(1):380-8. PubMed ID: 23144466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sex differences in the pharmacokinetics of dehydroepiandrosterone (DHEA) after single- and multiple-dose administration in healthy older adults.
    Frye RF; Kroboth PD; Kroboth FJ; Stone RA; Folan M; Salek FS; Pollock BG; Linares AM; Hakala C
    J Clin Pharmacol; 2000 Jun; 40(6):596-605. PubMed ID: 10868310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women.
    Mortola JF; Yen SS
    J Clin Endocrinol Metab; 1990 Sep; 71(3):696-704. PubMed ID: 2144295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status.
    Christiansen JJ; Andersen NH; Sørensen KE; Pedersen EM; Bennett P; Andersen M; Christiansen JS; Jørgensen JO; Gravholt CH
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):426-33. PubMed ID: 17302879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of a 3-week dehydroepiandrosterone administration on sleep, sex steroids and multiple 24-h hormonal profiles in postmenopausal women: a pilot study.
    Caufriez A; Leproult R; L'Hermite-Balériaux M; Kerkhofs M; Copinschi G
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):716-24. PubMed ID: 23488643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA.
    Ke Y; Gonthier R; Simard JN; Archer D; Lavoie L; Martel C; Vaillancourt M; Labrie F
    Horm Mol Biol Clin Investig; 2015 Dec; 24(3):117-29. PubMed ID: 26509785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey.
    Leblanc M; Labrie C; Bélanger A; Candas B; Labrie F
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4293-302. PubMed ID: 12970301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of oral dehydroepiandrosterone (DHEA) in the ovariectomised cynomolgus monkey.
    Leblanc M; Labrie C; Bélanger A; Candas B; Labrie F
    J Steroid Biochem Mol Biol; 2002 Jun; 81(2):159-64. PubMed ID: 12137806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Adrenopause and dehydroepiandrosterone: pharmacological therapy versus replacement therapy].
    Römmler A
    Gynakol Geburtshilfliche Rundsch; 2003 Apr; 43(2):79-90. PubMed ID: 12649580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men.
    Nestler JE; Beer NA; Jakubowicz DJ; Colombo C; Beer RM
    J Clin Endocrinol Metab; 1995 Feb; 80(2):700-6. PubMed ID: 7852539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An acute oral gavage study of 3beta-acetoxyandrost- 5-ene-7,17-dione (7-oxo-DHEA-acetate) in rats.
    Lardy H; Henwood SM; Weeks CE
    Biochem Biophys Res Commun; 1999 Jan; 254(1):120-3. PubMed ID: 9920743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial.
    Johannsson G; Burman P; Wirén L; Engström BE; Nilsson AG; Ottosson M; Jonsson B; Bengtsson BA; Karlsson FA
    J Clin Endocrinol Metab; 2002 May; 87(5):2046-52. PubMed ID: 11994339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men.
    Beer NA; Jakubowicz DJ; Matt DW; Beer RM; Nestler JE
    Am J Med Sci; 1996 May; 311(5):205-10. PubMed ID: 8615394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life.
    Barnhart KT; Freeman E; Grisso JA; Rader DJ; Sammel M; Kapoor S; Nestler JE
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3896-902. PubMed ID: 10566625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of delta-5-androstene-3beta, 17beta-diol with estradiol and dihydrotestosterone receptors in human myometrial and mammary cancer tissue.
    Poortman J; Prenen JA; Schwarz F; Thijssen JH
    J Clin Endocrinol Metab; 1975 Mar; 40(3):373-9. PubMed ID: 163841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of dehydroepiandrosterone supplementation during stressful military training: a randomized, controlled, double-blind field study.
    Taylor MK; Padilla GA; Stanfill KE; Markham AE; Khosravi JY; Ward MD; Koehler MM
    Stress; 2012 Jan; 15(1):85-96. PubMed ID: 21790446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Dehydroepiandrosterone and Testosterone Supplementation on Systemic Lipolysis.
    Espinosa De Ycaza AE; Rizza RA; Nair KS; Jensen MD
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1719-28. PubMed ID: 26885881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA.
    Labrie F; Cusan L; Gomez JL; Martel C; Bérubé R; Bélanger P; Chaussade V; Deloche C; Leclaire J
    J Steroid Biochem Mol Biol; 2008 May; 110(1-2):1-9. PubMed ID: 18359622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.